Author

H. Laeubli

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Research Focus:cell type annotation· 2 Research Focus:host-pathogen & immune response· 2 Organism:mouse· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

A. Zippelius· 2 shared A. Boersch· 1 shared A. Petrone· 1 shared A. S. Kashyap· 1 shared A. Tankasala· 1 shared A. Zingg· 1 shared B. Kasenda· 1 shared C. Guerrier· 1 shared

Activity by Year

2021-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 16 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

A. Zippelius

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Variable PD-1 glycosylation modulates the activity of immune checkpoint inhibitors

C.-W. Chu, T. Caval, F. Alisson-Silva, A. Tankasala, C. Guerrier, G. Czerwieniec, H. Laeubli, F. Schwarz

This study shows that PD-1 glycosylation variants affect the efficacy of immune checkpoint inhibitors and suggests personalized therapeutic approaches.

bioRxiv · Aug 25, 2023Immunology

Engagement of sialylated glycans with Siglec receptors on myeloid suppressor cells inhibit anti-cancer immunity via CCL2

R. Wieboldt, E. Carlini, L. Chia-wei, A. Boersch, A. Zingg, D. Lardinois, P. Herzig, L. Don, A. Zippelius, H. Laeubli, N. Rodrigues Mantuano

This study shows that sialylated glycans on myeloid suppressor cells interact with Siglec receptors to suppress anti-cancer immunity through CCL2-mediated mechanisms.

bioRxiv · Jun 29, 2023 · PreprintImmunology

Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade

M. A. Stanczak, N. R. Mantuano, N. Kirchhammer, D. E. Sanin, J. Wang, M. P. Trefny, G. Monaco, M. A. Gray, A. Petrone, A. S. Kashyap, K. Glatz, B. Kasenda, K. Normington, J. Broderick, L. Peng, , H. Laeubli

This study shows that targeting cancer glycosylation with an antibody-sialidase conjugate repolarizes tumor-associated macrophages and enhances immune checkpoint blockade efficacy in mouse models.

bioRxiv · Apr 11, 2021Immunology